Naveris, Inc.

Naveris, Inc is a Waltham, Massachusetts-based molecular diagnostics company focused on transforming cancer detection. We develop and commercialize highly sensitive blood tests, known as liquid biopsies, that identify viral cancers significantly earlier than traditional methods. Our flagship product, NavDx®, utilizes proprietary technology to detect tumor-tissue-modified DNA (TTMV) in blood, enabling real-time monitoring of HPV-related cancers and facilitating early detection of recurrence.

At Naveris, our mission is to deliver disruptive technology with the potential to transform cancer detection and improve patient outcomes. We are dedicated to providing clinicians with a powerful tool for proactive surveillance and personalized treatment strategies.

Naveris’ technology has demonstrated significant advantages in detecting cancer recurrence, with NavDx® establishing a lead-time of up to 3.9 months in clinical studies.

We are a growing team of scientists and experts committed to advancing the field of liquid biopsy and ultimately, saving lives.